Source comparison
Melanotan-2 Science Explained: Peptide Comparison
Understanding how Melanotan-2 differs from related compounds and endogenous hormones clarifies its unique pharmacological profile and research applications. Alpha-MSH (endogenous) Non-selective MC1R–MC5R agonist, moderate affinity 7–20 minutes Natural melanoco
This comparison does not assign a generated winner or score.
- Understanding how Melanotan-2 differs from related compounds and endogenous hormones clarifies its unique pharmacological profile and research applications.
- Alpha-MSH (endogenous)
- Non-selective MC1R–MC5R agonist, moderate affinity
- 7–20 minutes
- Natural melanocortin signaling reference
- Rapidly degraded by neutral endopeptidases, requires continuous secretion for sustained effect
- Melanotan-2
- Non-selective MC1R–MC5R agonist, high affinity, MC4R-preferring
- ~33 minutes plasma, 6–8h receptor activation
- Photoprotection, appetite regulation, metabolic studies, sexual function research
- Cyclized structure confers enzymatic resistance; crosses blood-brain barrier efficiently for central effects
- Melanotan-1 (afamelanotide)
- Highly MC1R-selective, minimal MC3R/MC4R activity
- ~30 minutes
- Erythropoietic protoporphyria photoprotection, vitiligo repigmentation
- Linear peptide structure limits CNS penetration, produces melanogenesis without appetite or behavioral effects
- Bremelanotide (PT-141)
- MC3R/MC4R-selective, minimal MC1R activity
- ~2.7 hours
- Hypoactive sexual desire disorder research
- Desamino-MT-2 derivative optimized for central effects with reduced pigmentation response
- Setmelanotide
- Highly MC4R-selective agonist
- ~2.5 hours
- POMC/LEPR deficiency obesity treatment research
- FDA-approved for genetic obesity syndromes; designed to avoid MC1R pigmentation while maximizing appetite suppression
- The comparison reveals Melanotan-2's non-selectivity creates its characteristic multi-system effects. Researchers studying isolated melanogenesis typically prefer Melanotan 1 for its MC1R selectivity and minimal central activity, while those investigating appetite mechanisms choose MC4R-selective compounds. MT-2 remains the reference standard when research protocols require simultaneous peripheral and central melanocortin activation, particularly in photoprotection studies that also measure metabolic parameters or in metabolic studies that document pigmentation as a biomarker of melanocortin receptor engagement. The compound's pharmacokinetic profile. Short plasma half-life but extended receptor occupancy. Allows once-daily administration in most protocols while maintaining steady-state tissue effects.